Sun Primes Late-Stage Psoriasis Asset With Samsung Manufacturing Deal
Executive Summary
Sun Pharma has firmed up a manufacturing pact for tildrakizumab with Samsung BioLogics, securing supplies of its late-stage psoriasis asset in an increasingly competitive segment. The deal also underscores Samsung’s expanding stature as a frontline CMO in the biologics space.
You may also be interested in...
Indo-Korean Pharma Linkages: A New Emerging Asian Front?
Is there a new strategic Asian pharma partnership in the works? Early days perhaps but worth keeping an eye on the India-South Korea deal street.
Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended
The latest drug development news and highlights from our US FDA Performance Tracker.
Sun Q3 Profits Dive, Halol Resolution Stays Pivotal To Trigger Reset
Sun Pharma reported a sharp decline in Q3 profits, dented by tax adjustments related to changes in US tax rates and continuing pricing pressures there. With Q4 revenues expected to to be "similar” to Q3, all eyes are on the Halol site making the compliance cut and the upcoming PDUFA date for Sun’s psoriasis asset.